Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04561518 · ClinicalTrials.gov registry record

ConTTRibute: A Global Observational Study of Patients With Transthyretin (TTR)-Mediated Amyloidosis (ATTR Amyloidosis)

A clinical trial of ATTR Amyloidosis and Transthyretin-Mediated Amyloidosis, sponsored by Alnylam Pharmaceuticals.

Recruiting
Registry status
1,500
Enrollment target
20
Study locations

NCT04561518 is a study of ATTR Amyloidosis and Transthyretin-Mediated Amyloidosis that is actively recruiting participants, run by Alnylam Pharmaceuticals. The registered enrollment target is 1,500 participants. The trial reports 20 study locations across 12 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04561518, a study of ATTR Amyloidosis and Transthyretin-Mediated Amyloidosis, is actively recruiting participants, sponsored by Alnylam Pharmaceuticals.

RECRUITING
Registry status
1,500 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this study is to: * Describe epidemiological and clinical characteristics, natural history and real-world clinical management of ATTR amyloidosis patients * Characterize the safety and effectiveness of patisiran and vutrisiran as part of routine clinical practice in the real-world clinical setting * Describe disease emergence/progression in pre-symptomatic carriers of a known disease-causing transthyretin (TTR) variant

Study Locations (20)

Other

  • Clinical Trial Site - Salvador
  • Clinical Trial Site - São Paulo
  • Clinical Trial Site - Sofia
  • Clinical Trial Site - Aarhus
  • Clinical Trial Site - Copenhagen
  • Clinical Trial Site - Bordeaux
  • Clinical Trial Site - Bron

California

  • Clinical Trial Site - La Jolla
  • Clinical Trial Site - Los Angeles

Texas

  • Clinical Trial Site - Austin
  • Clinical Trial Site - Houston

Florida

  • Clinical Trial Site - Jacksonville

Iowa

  • Clinical Trial Site - Iowa City

Kansas

  • Clinical Trial Site - Kansas City

Maryland

  • Clinical Trial Site - Baltimore

Massachusetts

  • Clinical Trial Site - Boston

Trial Details

FieldValue
Enrollment Target 1,500 participants
Start Date 2020-11-23
Est. Completion 2030-09-01

Sponsor

Alnylam Pharmaceuticals

49 total trials

What the Registry Record Tells You About NCT04561518

The ClinicalTrials.gov registry entry for NCT04561518 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 1,500 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alnylam Pharmaceuticals, which has 49 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with ATTR Amyloidosis appearing as the primary indexed condition, and to 0 interventions.

NCT04561518 reports 20 study locations spanning 12 distinct geographic areas - top geographies include Other, California, Texas.

Frequently Asked Questions

What is clinical trial NCT04561518 about?

NCT04561518 is a clinical study titled "ConTTRibute: A Global Observational Study of Patients With Transthyretin (TTR)-Mediated Amyloidosis (ATTR Amyloidosis)". The purpose of this study is to: * Describe epidemiological and clinical characteristics, natural history and real-world clinical management of ATTR amyloidosis patients * Characterize the safety and effectiveness of patisiran and vutrisiran as part of routine clinical practice in the real-world cl...

What is the current status of trial NCT04561518?

This trial is currently recruiting. The enrollment target is 1,500 participants. The study started on 2020-11-23. Estimated completion is 2030-09-01.

What conditions does trial NCT04561518 study?

This clinical trial studies the following conditions: ATTR Amyloidosis, Transthyretin-Mediated Amyloidosis.

Who is sponsoring clinical trial NCT04561518?

This trial is sponsored by Alnylam Pharmaceuticals, which has 49 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04561518 being conducted?

This trial has 20 study locations across California, Florida, Iowa, Kansas, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for ATTR Amyloidosis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.